FindA University Ltd Featured PhD Programmes
FindA University Ltd Featured PhD Programmes
FindA University Ltd Featured PhD Programmes

Gene variant driven sub-stratification of breast cancer patients (MRC CASE).

Faculty of Biology, Medicine and Health

This project is no longer listed on and may not be available.

Click here to search for PhD studentship opportunities
Prof P Townsend , Dr O Cexus , Prof A D Whetton No more applications being accepted Competition Funded PhD Project (European/UK Students Only)

About the Project

Current breast cancer diagnosis relies on binary (positive/negative) values for estrogen/progesterone hormone receptors (HR), and HER2 receptor values. Together, these form the hormone receptor status (HRS), which is closely linked to clinical breast cancer treatment decisions. It is increasingly recognised that breast cancer is an extremely heterogenous disease which in reality represents many varied subtypes. As a result of treatment decisions based around a binary classification system, patient outcomes are highly varied, difficult to predict, and there are limited means to personalise chemotherapy. Increasingly, the field is looking for methods to move beyond hormone receptor status to further stratify patients in a more granular fashion, one promising way to do this is using gene variants.

The aim of this current project is to develop a computational model to link genetic variants to the sub-stratified phenotypic hormone expression and resulting tumour microenvironment. With our industrial partner Onkolyze, we will develop a system that will allow scientists and clinicians to classify breast cancer into “genetic subtypes” and potentially design personalised treatment strategies with higher efficacy for these subtypes.

The student will develop a AI model that can link gene variants to hormone receptor percentage expression, which is currently characterised during existing clinical pathology workflow. This model will predict the resultant phenotypes and possible drug-cell interactions of these phenotypes. Our models utility will be validated in patient-derived cell lines and patient-derived microenvironments from the MCRC biobank and collaborators, for imaging modality analysis. This will enable the prediction of treatment outcomes based on genetic variants found in patient tissue at a cellular level without deviating significantly from existing clinical workflow.

The student will receive a broad interdisciplinary skills training in bioinformatics applied to personalised oncology; specifically, they will be trained in state-of-the-art techniques from AI/machine learning, neural networks, bioinformatics, and statistics. In addition, via the validation steps they will learn in-vitro analytical, technical and cell biology methods including cell culture and immunofluorescence microscopy. The student will gain a strong theoretical understanding in the relevant background theory (e.g. cell cycle, DNA replication, chemotherapy approaches, clinical workflow, and cancer). The student will also develop an understanding of a multidisciplinary approach to modelling and collaboration via our industrial partner’s existing on-going collaborations and those at UoM.

At the end of the PhD the student will have a body of work suitable for a high-quality thesis, multiple high impact publications, a strong interdisciplinary skill set and industry links, making them extremely competitive for posts in pharma/biotech or academia.

• Townsend lab website -
• Manchester Cancer Research Centre -
• Onkolyze website –

Entry Requirements:
Applications are invited from UK/EU nationals only. Applicants must have obtained, or be about to obtain, at least an upper second class honours degree (or equivalent) in a relevant subject.

Funding Notes

This is a CASE studentship in partnership with Onkolyze Ltd and will be funded under the MRC Doctoral Training Programme. If you are interested in this project, please make direct contact with the Supervisor to discuss the project further as soon as possible. You MUST also submit an online application form - full details on how to apply can be found here

As an equal opportunities institution we welcome applicants from all sections of the community regardless of gender, ethnicity, disability, sexual orientation and transgender status. All appointments are made on merit.


Guinney, J., Dienstmann, R., Wang, X. et al. The consensus molecular subtypes of colorectal cancer. Nat Med 21, 1350–1356 (2015).

Fragomeni, S.M., Sciallis, A., and Jeruss, J.S. Molecular subtypes and local-regional control of breast cancer Surg Oncol Clin N Am., 7(1):95-120 (2018).

Vidula, N., Yau, C., Wolf, D. and Rugo, H. S. Androgen receptor gene expression in primary breast cancer. NPJ Breast Cancer, 5:47 (2019).

Daemen, A. and Manning, G. HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumours. Breast Cancer Res. 20:8 (2018).

Waterfield, S., Sheraton, V.M., Wilding, R., and Townsend, P.A. Neural network and differential expression analyses of non-binary hormone receptor and HER2 receptor values in breast cancer to discover clinically actionable genes. Submitted to Journal of Hematology & Oncology (2020).

Search Suggestions

Search Suggestions

Based on your current searches we recommend the following search filters.

FindAPhD. Copyright 2005-2020
All rights reserved.